Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025 or the MIRACLE Medical Technology Act of 2025This bill requires the Department of Health and Human Services (HHS) to implement a program for the United States and Israel to collaborate on developing and delivering health care products and services. The program must include coordinated activities in specified areas, including research and development, use of innovative technology, intellectual property protection, regulatory harmonization, disease prevention, and biological product manufacturing. The bill authorizes HHS to establish a joint United States-Israel Health Care Collaboration Center in the United States to leverage existing expertise for advancing the program’s purposes.

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

Restoring Trade Fairness ActThis bill establishes various trade measures related to China, including by revoking China's permanent normal trade relations (PNTR) status and increasing the rates of duty (i.e., tariffs) on Chinese imported goods. The bill prohibits imported goods originating from North Korea, China, Russia, or Iran from receiving de minimis treatment. (Current law allows for U.S. imports under a de minimis threshold of $800 per shipment to enter free of tariffs, fees, and taxes.)Specifically, the bill revokes China's PNTR status. Currently, China's PNTR status allows for Chinese goods to have duty rates set forth in column 1 of the Harmonized Tariff Schedule of the United States (HTS). With the removal of China's PNTR status, the bill generally sets the applicable duty rates on imported Chinese goods at the higher rates listed in column 2 of the HTS, with exceptions.The bill establishes a minimum duty rate of 35% for all Chinese goods, which requires column 2 rates to be at least 35%. However, the bill establishes a minimum duty rate of 100% for a list of specified goods (e.g., various minerals, certain vaccines and drugs, and certain defense-related articles). Duty rates are phased in over five years and adjusted annually for inflation.The bill alsoauthorizes the President to take additional actions related to trade with China, requires merchandise imported from China to be appraised based on U.S. value, and establishes a trust fund to compensate U.S. producers for lost revenue resulting from retaliatory actions by China.

Domestic Security Using Production Partnerships and Lessons from Yesterday Act of 2025 or the Domestic SUPPLY Act of 2025This bill establishes a program and sets out other requirements to promote domestic manufacturing of personal protective equipment (PPE) to address infectious diseases and other public health emergencies.Specifically, the Department of Health and Human Services (HHS) must establish a program to enter into purchasing agreements with eligible domestic manufacturers for PPE to prepare for and respond to public health emergencies. To be eligible, manufacturers must be majority owned and operated by U.S. citizens and must manufacture a majority of their contracted products domestically, with 100% of products manufactured domestically by 2028. HHS must coordinate with the Department of Defense and the Department of Homeland Security on this program.In addition, the federal government must only procure, subject to limited exceptions, clothing or equipment that is produced domestically to prevent the transmission of an infectious disease. If using federal funds, states or localities must also procure such items domestically.Further, the bill requires HHS to submit to Congress a report about changes to federal requirements for PPE since the beginning of the COVID-19 pandemic and the impact of those changes on health care workers who cared for patients in 2020 and 2021.

Restoring Confidence in the World Anti-Doping Agency Act of 2025

No Abortion Coverage for Medicaid ActThis bill prohibits the Centers for Medicare & Medicaid Services from approving experimental, pilot, or demonstration projects under Medicaid (also known as Section 1115 Demonstrations) if the project provides federal financial assistance for abortions or for health benefits that include abortions, including expenses for related travel or lodging.The bill's restrictions do not apply to abortions in the cases of rape or incest; treatments to address life-threatening physical disorders, injuries, or illnesses; or treatments for miscarriages or ectopic pregnancies.

Green Tape Elimination Act of 2025

Recognizing the roles and the contributions of Americas Certified Registered Nurse Anesthetists (CRNAs) and their critical role in providing quality health care for the public and the Nation's Armed Forces for more than 150 years and through multiple public health emergencies and beyond.

Prohibiting Abortion Industry’s Lucrative Loopholes Act

This joint resolution nullifies the Environmental Protection Agency rule titled Phasedown of Hydrofluorocarbons: Management of Certain Hydrofluorocarbons and Substitutes Under the American Innovation and Manufacturing Act of 2020 and published on October 11, 2024. The rule establishes an emission reduction and reclamation program for the management of hydrofluorocarbons, which are greenhouse gases. The rule also establishes alternative Resource Conservation and Recovery Act standards for certain ignitable spent refrigerants being recycled for reuse.

Reaffirming the freedom to decide and expressing continued support for medication abortion access.

Alexandra’s Law Act of 2025

Sustainable Cardiopulmonary Rehabilitation Services in the Home Act This bill permanently allows services relating to cardiac rehabilitation programs, intensive cardiac rehabilitation programs, and pulmonary rehabilitation programs to be furnished via telehealth at a beneficiary's home under Medicare.

Dignity for Aborted Children ActThis bill establishes requirements for abortion providers with respect to the disposal of human fetal tissue from an abortion.Specifically, it requires abortion providers to obtain a patient's informed consent for one of two specified methods of disposition and to retain the corresponding documentation in the patient's file.First, patients may choose to retain possession of the tissue. A patient may choose to transfer the tissue to an entity that provides interment or cremation services.Second, patients may choose to release the tissue to the provider. Providers must ensure any tissue released to them is interred or cremated within seven days of the procedure in a manner consistent with state law regarding the disposal of human remains.Abortion providers must submit reports annually to the Department of Health and Human Services about these requirements and other specified information.The bill establishes civil penalties for violations of the requirement to retain documentation of informed consent, and it establishes criminal penalties for violations of the requirement regarding the disposal of human fetal tissue.

Ultrasounds Save Lives Act of 2025